Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial

The authors updated their report on a randomized trial initiated in 1982 comparing, in early breast cancer, high-dose IM Medroxyprogesterone acetate (HD-MPA) adjuvant hormonotherapy during 6 months with no hormonotherapy; node-positive patients also received 6 courses of IV CMF (day 1, day 8; q.4 we...

Descripción completa

Detalles Bibliográficos
Autores principales: Focan, C, Beauduin, M, Salamon, E, Greve, J de, Wasch, G de, Lobelle, J P, Majois, F, Tagnon, A, Tytgat, J, Belle, S van, Vandervellen, R, Vindevoghel, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363916/
https://www.ncbi.nlm.nih.gov/pubmed/11437394
http://dx.doi.org/10.1054/bjoc.2001.1829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363916/
https://www.ncbi.nlm.nih.gov/pubmed/11437394
http://dx.doi.org/10.1054/bjoc.2001.1829

Ejemplares similares